标题
A review of the safety and efficacy of current COVID-19 vaccines
作者
关键词
-
出版物
Frontiers of Medicine
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-05
DOI
10.1007/s11684-021-0893-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
- (2021) Xiaoying Shen et al. Cell Host & Microbe
- Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021
- (2021) Tom T. Shimabukuro et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity
- (2021) Matthew A Spinelli et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
- (2021) Kimberly G. Blumenthal et al. NEW ENGLAND JOURNAL OF MEDICINE
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
- (2021) Noa Dagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines
- (2021) John M. Kelso VACCINE
- A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
- (2021) Dean Follmann et al. ANNALS OF INTERNAL MEDICINE
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
- (2021) Pengfei Wang et al. Cell Host & Microbe
- US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
- (2021) Isaac See et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
- (2021) Eleftheria Vasileiou et al. LANCET
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- (2021) Katherine R W Emary et al. LANCET
- Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study
- (2021) Dan Frampton et al. LANCET INFECTIOUS DISEASES
- Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
- (2021) Nicholas G. Davies et al. NATURE
- COVID-19 dynamics after a national immunization program in Israel
- (2021) Hagai Rossman et al. NATURE MEDICINE
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
- (2021) Xiaoying Shen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
- (2021) Marie Scully et al. NEW ENGLAND JOURNAL OF MEDICINE
- Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
- (2021) Guo-Lin Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
- (2021) Mark G. Thompson et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial
- (2021) Daniel Freeman et al. Lancet Public Health
- SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
- (2021) Chihiro Motozono et al. Cell Host & Microbe
- COVID-19 vaccines and thrombosis with thrombocytopenia syndrome
- (2021) Chih-Cheng Lai et al. Expert Review of Vaccines
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
- (2021) Nawal Al Kaabi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals
- (2021) Gajanan N Sapkal et al. JOURNAL OF TRAVEL MEDICINE
- Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants
- (2021) Angela Choi et al. JOURNAL OF VIROLOGY
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
- (2021) Emma C Wall et al. LANCET
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
- (2021) Mine Durusu Tanriover et al. LANCET
- Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
- (2021) Yuxin Chen et al. LANCET INFECTIOUS DISEASES
- BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
- (2021) Jianying Liu et al. NATURE
- mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
- (2021) Hiam Chemaitelly et al. NATURE MEDICINE
- First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
- (2021) C. R. Simpson et al. NATURE MEDICINE
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
- (2021) Alejandro Jara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
- (2021) Paul T. Heath et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
- (2021) Mark G. Thompson et al. NEW ENGLAND JOURNAL OF MEDICINE
- B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
- (2021) Hao Zhou et al. mBio
- Covid-19 vaccination hesitancy
- (2021) Mohammad S Razai et al. BMJ-British Medical Journal
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
- (2020) Shengli Xia et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
- (2020) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 vaccine trial ethics once we have efficacious vaccines
- (2020) David Wendler et al. SCIENCE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Vaccine impact: Benefits for human health
- (2016) Mark Doherty et al. VACCINE
- Strategies for addressing vaccine hesitancy – A systematic review
- (2015) Caitlin Jarrett et al. VACCINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started